Reference
Protocol Rating Combinations
All 27 possible combinations of Evidence × Risk × Cost rendered as inline badges. Three representative card variants follow.
Evidence: established
Evidence established
Risk negligible
Cost low
Evidence established
Risk negligible
Cost moderate
Evidence established
Risk negligible
Cost high
Evidence established
Risk moderate
Cost low
Evidence established
Risk moderate
Cost moderate
Evidence established
Risk moderate
Cost high
Evidence established
Risk significant
Cost low
Evidence established
Risk significant
Cost moderate
Evidence established
Risk significant
Cost high
Evidence: emerging
Evidence emerging
Risk negligible
Cost low
Evidence emerging
Risk negligible
Cost moderate
Evidence emerging
Risk negligible
Cost high
Evidence emerging
Risk moderate
Cost low
Evidence emerging
Risk moderate
Cost moderate
Evidence emerging
Risk moderate
Cost high
Evidence emerging
Risk significant
Cost low
Evidence emerging
Risk significant
Cost moderate
Evidence emerging
Risk significant
Cost high
Evidence: experimental
Evidence experimental
Risk negligible
Cost low
Evidence experimental
Risk negligible
Cost moderate
Evidence experimental
Risk negligible
Cost high
Evidence experimental
Risk moderate
Cost low
Evidence experimental
Risk moderate
Cost moderate
Evidence experimental
Risk moderate
Cost high
Evidence experimental
Risk significant
Cost low
Evidence experimental
Risk significant
Cost moderate
Evidence experimental
Risk significant
Cost high
Card Variant Examples
Protocol Rating
Evidence established
Risk negligible
Cost low
Creatine monohydrate — decades of research, minimal risk, inexpensive.
Protocol Rating
Evidence emerging
Risk moderate
Cost moderate
NMN supplementation — promising but incomplete evidence, moderate cost.
Protocol Rating
Evidence experimental
Risk significant
Cost high
Novel peptide therapy — early-stage, significant risk profile, high cost.